Log In
Print this Print this

RayVa, alprostadil

  Manage Alerts
Collapse Summary General Information
Company Apricus Biosciences Inc.
DescriptionTopical formulation of 0.42% alprostadil -- prostaglandin E1 (PGE1) -- formulated with Apricus' NexACT transdermal delivery technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationRaynaud's disease
Indication DetailsTreat Raynaud's disease secondary to scleroderma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today